CRISPR-Cas9 is a programmable gene editing tool with a promising potential for cancer gene therapy. This therapeutic function is enabled in the present work via the non-covalent delivery of CRISPR ribonucleic protein (RNP) by cationic glucosamine/PEI-derived graphene quantum dots (PEI-GQD) that aid in overcoming physiological barriers and tracking genes of interest. PEI-GQD/RNP complex targeting the TP53 mutation overexpressed in ~50% of cancers successfully produces its double-stranded breaks in solution and in PC3 prostate cancer cells. Restoring this cancer "suicide" gene can promote cellular repair pathways and lead to cancer cell apoptosis. Its repair to the healthy form performed by simultaneous PEI-GQD delivery of CRISPR RNP and a gene repair template leads to a successful therapeutic outcome: 40% apoptotic cancer cell death, while having no effect on non-cancerous HeK293 cells. The translocation of PEI-GQD/RNP complex into PC3 cell cytoplasm is tracked via GQD intrinsic fluorescence, while EGFP-tagged RNP is detected in the cell nucleus, showing the successful detachment of the gene editing tool upon internalization. Using GQDs as non-viral delivery and imaging agents for CRISPR-Cas9 RNP sets the stage for image-guided cancer-specific gene therapy.
Advanced functional materials. 2023 Jul 12 [Epub]
Bong Lee, Klara Gries, Alina R Valimukhametova, Ryan L McKinney, Roberto Gonzalez-Rodriguez, Ugur C Topkiran, Jeffery Coffer, Giridhar R Akkaraju, Anton V Naumov
Department of Physics and Astronomy, Texas Christian University, Fort Worth, TX., Department of Chemistry and Biochemistry, Heidelberg University, Heidelberg, Germany., Department of Physics, University of North Texas, Denton, TX., Department of Chemistry and Biochemistry, Texas Christian University, Fort Worth, TX., Department of Biology, Texas Christian University, Fort Worth, TX.